PH 3

Drug Profile

PH 3

Alternative Names: PH3; PHN-031; PHN-033

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhytoHealth
  • Class Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Postmenopausal osteoporosis

Most Recent Events

  • 17 Feb 2016 PH 3 is still in phase II trials for Postmenopausal osteoporosis (Prevention) and Diabetic nephropathies in Taiwan
  • 31 Jul 2011 PhytoHealth completes a phase II trial in Postmenopausal osteoporosis in Taiwan (NCT00693667)
  • 31 Aug 2010 Phase-II clinical trials in Diabetic nephropathies in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top